Avalo Therapeutics, Inc. Financial Ratios
AVTX|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -3.59 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-94.2%
Profit Margin
-132642.4%
Net Income / Revenue
Asset Turnover
0.00
Revenue / Total Assets
Equity Multiplier
1.40
Total Assets / Equity
Composite: -94.2% (reported: -94.2%)
Profitability
Liquidity
Current Ratio
8.14
Quick Ratio
8.14
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.00
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
Earnings Quality
Accrual Ratio
-20.1%
-29.3pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.